Who
William G. Rice
Chair, President & CEO
Company insider
Files Form 4 as: Chair, President & CEO, Aptose Biosciences.
In numbers
- Trades disclosed
- 49
- Buys
- 11
- Sells
- 1
- Bought
- $193K
- Sold
- $1.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jan 2019
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $1.1M613,252 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —300,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —70,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —70,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —600,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —700,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —343,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —2,000,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —300,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.